Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: Case-control study of 23 471 primary care patients

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 7, 2014, Pages 827-834

  Ford, A C ^a,b   Talley, N J ^c   Walker, M M ^c   Jones, M P ^d  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE CONTROL STUDY; CHRONIC IDIOPATHIC CONSTIPATION; CONSTIPATION; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DYSPEPSIA; ENDOCRINE DISEASE; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; RHEUMATIC DISEASE; ADOLESCENT; AGED; AUTOIMMUNE DISEASES; GASTROINTESTINAL DISEASES; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PREVALENCE; PRIMARY HEALTH CARE; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; CONSTIPATION; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; PRIMARY HEALTH CARE; YOUNG ADULT;

EID: 84908109006     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12903     Document Type: Article

References (71)

1. Chey WD, Nojkov B, Rubenstein JH, Dobhan R, Greenson JK, Cash BD. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol 2010; 105: 859-65.
2. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8: 830-7.
3. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-80.
4. Lovell RM, Ford AC. Global prevalence of, and risk factors for, irritable bowel syndrome: a metaanalysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
5. Moayyedi P, Forman D, Braunholtz D, et al. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 2000; 95: 1448-55.
6. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 1582-91.
7. Talley NJ, Zinsmeister AR, Van Dyke C, Melton L. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101: 927-34.
8. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ III. Dyspepsia and dyspepsia subgroups: a populationbased study. Gastroenterology 1992; 102: 1259-68.
9. Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ III. Functional constipation and outlet delay: a population-based study. Gastroenterology 1993; 105: 781-90.
10. Cann PA, Read NW, Brown C, Hobson A, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983; 24: 405-11.
11. McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility. Dig Dis Sci 1993; 38: 1761-2.
12. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 2011; 140: 91-100.
13. Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC. Heightened visceral sensation in functional gastrointestinal disease is not sitespecific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995; 40: 1607-13.
14. Zhou G, Qin W, Zeng F, et al. Whitematter microstructural changes in functional dyspepsia: a diffusion tensor imaging study. Am J Gastroenterol 2013; 108: 260-9.
15. Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA. Gastric accomodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003; 1: 264-72.
16. Quartero AO, de Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998; 43: 2028-33.
17. Salet GA, Samsom F, Roelofs JM, van Berge Henegouwen GP, Smout AJ, Akkermans LM. Responses to gastric distension in functional dyspepsia. Gut 1998; 42: 823-9.
18. Vandenberghe J, Vos R, Persoons P, Demyttenaere K, Janssens J, Tack J. Dyspeptic patients with visceral hypersensitivity: sensitisation of pain specific or multimodal pathways? Gut 2005; 54: 914-9.
19. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33.
20. Annahazi A, Ferrier L, Bezirard V, et al. Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipationpredominant IBS. Am J Gastroenterol 2013; 108: 1322-31.
21. Lee H, Park JH, Park DI, et al. Mucosal mast cell count is associated with intestinal permeability in patients with diarrhea predominant irritable bowel syndrome. Neurogastroenterol Motil 2013; 19: 244-50.
22. Matricon J, Meleine M, Gelot A, et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 36: 1009-31.
23. Vanheel H, Vicario M, Vanuytsel T, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut 2013;. doi:10.1136/gutjnl-2012-303857
24. Martinez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2013; 62: 1160-8.
25. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
26. Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia, and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29: 765-73.
27. Coeffier M, Gloro R, Boukhettala N, et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 2010; 105: 1181-8.
28. Liebregts T, Adam B, Bredack C, et al. Small bowel homing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol 2011; 106: 1089-98.
29. Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: genderdependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
30. Lee KJ, Kim YB, Kim JH, Kwon HK, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008; 23: 1689-94.
31. Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1175-83.
32. Floreani A, Betterle C, Baragiotta A, et al. Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy. Dig Liver Dis 2002; 34: 258-61.
33. Volta U, Ravaglia G, Granito A, et al. Coeliac disease in patients with autoimmune thyroiditis. Digestion 2001; 64: 61-5.
34. Not T, Tommasini A, Tonini G, et al. Undiagnosed coeliac disease and risk of autoimmune disorders in subjects with Type I diabetes mellitus. Diabetologia 2001; 44: 151-5.
35. Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106: 110-9.
36. Sjoberg K, Lindgren S, Eriksson S. Frequent occurrence of non-specific gliadin antibodies in chronic liver disease. Endomysial but not gliadin antibodies predict coeliac disease in patients with chronic liver disease. Scand J Gastroenterol 1997; 32: 1162-7.
37. Jones MP, Walker MM, Ford AC, Talley NJ. The overlap of atopy and functional gastrointestinal disorders among 23 471 patients in primary care. Aliment Pharmacol Ther 2014; 40: 382-91.
38. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011; 19: 251-5.
39. The Health Improvement Network website. Available at: http://www. thin-uk.com/. Accessed 12 July 2014.
40. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401.
41. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
42. Chisholm J. The Read clinical classification. Br Med J 1990; 300: 1092.
43. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
44. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.
45. Gladman LM, Gorard DA. General practitioner and hospital specialist attitudes to functional gastrointestinal disorders. Aliment Pharmacol Ther 2003; 17: 651-4.
46. Engsbro AL, Begtrup Lm, Kjeldsen J, et al. Patients suspected of irritable bowel syndrome-Cross-sectional study exploring the sensitivity of Rome III criteria in primary care. Am J Gastroenterol 2013; 108: 972-80.
47. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol 1997; 9: 689-92.
48. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 991-1000.
49. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671-80.
50. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8: 401-9.
51. Lovell RM, Ford AC. Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a metaanalysis. Am J Gastroenterol 2012; 107: 1793-801.
52. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol 2011; 46: 421-31.
53. Franke A, Singer MV, Dumitrascu DL. How general practitioners manage patients with irritable bowel syndrome. Data from a German urban area. Rom J Intern Med 2009; 47: 47-53.
54. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262-70.
55. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P. The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions. Gastroenterology 2014; 146: 932-40.
56. Kindt S, van Oudenhove L, Broekaert D, et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009; 21: 389-98.
57. Vaahtuvuo J, Munukka E, Korkeamaki M, Luukkainen R, Toivanen P. Fecal microbiota in early rheumatoid arthritis. J Rheumatol 2008; 35: 1500-5.
58. Stebbings SM, Taylor C, Tannock GW, Baird MA, Highton J. The immune response to autologous bacteroides in ankylosing spondylitis is characterized by reduced interleukin 10 production. J Rheumatol 2009; 36: 797-800.
59. Murri M, Leiva I, Gomez-Zumaquero JM, et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med 2013; 11: 46.
60. Mori K, Nakagawa Y, Ozaki H. Does the gut microbiota trigger Hashimoto's thyroiditis? Discov Med 2012; 14: 321-6.
61. Pohl J, Ring A, Stremmel W, Stiehl A. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2006; 18: 69-74.
62. da Rocha Sobrinho HM, Jarach R, da Silva NA, et al. Mycoplasmal lipidassociated membrane proteins and Mycoplasma arthritidis mitogen recognition by serum antibodies from patients with rheumatoid arthritis. Rheumatol Int 2011; 31: 951-7.
63. Sechi LA, Rosu V, Pacifico A, Fadda G, Ahmed N, Zanetti S. Humoral immune responses of type 1 diabetes patients to Mycobacterium avium subsp. paratuberculosis lend support to the infectious trigger hypothesis. Clin Vaccine Immunol 2008; 15: 320-6.
64. Garcia Carrasco M, Mendoza Pinto C, Lopez Colombo A, et al. Irritable bowel syndrome-type symptoms in female patients with mild systemic lupus erythematosus: frequency, related factors and quality of life. Neurogastroenterol Motil 2013; 25: 958-66.
65. Wood JD, Liu S, Drossman DA, Ringel Y, Whitehead WE. Anti-enteric neuronal antibodies and the irritable bowel syndrome. J Neurogastroenterol Motil 2012; 18: 78-85.
66. Ohlsson B, Ekblad E, Veress B, Montgomery A, Janciauskiene S. Antibodies against gonadotropinreleasing hormone (GnRH) and destruction of enteric neurons in 3 patients suffering from gastrointestinal dysfunction. BMC Gastroenterol 2010; 10: 10-48.
67. Tornblom H, Lang B, Clover L, Knowles CH, Vincent A, Lindberg G. Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scand J Gastroenterol 2007; 42: 1289-93.
68. Pittock SJ, Lennon VA, Dege CL, Talley NJ, Locke GR 3rd. Neural autoantibody evaluation in functional gastrointestinal disorders: a population-based casecontrol study. Dig Dis Sci 2011; 56: 1452-9.
69. Quan C, Talley NJ, Jones MP, Howell S, Horowitz M. Gastrointestinal symptoms and glycemic control in diabetes mellitus: a longitudinal population study. Eur J Gastroenterol Hepatol 2008; 20: 888-97.
70. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus. Arch Intern Med 2001; 161: 1989-96.
71. Yurkovetskiy L, Burrows M, Khan AA, et al. Gender bias in autoimmunity is influenced by microbiota. Immunity 2013; 39: 400-12.